Acute severe community-acquired pneumonia: nosocomial complications and prevention · ICU Topics

ICU scene of a ventilated patient with a chest X-ray showing a new infiltrate, a central-line dressing, an oral-care tray with chlorhexidine, and a head-of-bed angle gauge at 30 degrees, clinical-blue lighting — FigureNosocomial complications in the ventilated CAP patient — VAP is the #1 superinfection (>48 h after intubation). The fastest way to prevent VAP is to extubate: daily SAT + SBT, head-up 30-45 degrees, subglottic suction, chlorhexidine, and daily line review.

Clinical pearls

High-yight nosocomial complications points for the CICM/FFICM exam

VAP: #1 nosocomial infection in ventilated CAP patients. Different organisms from initial CAP (healthcare-associated).[1] }
CRBSI: from central venous catheter. Prevent with full barrier precautions + chlorhexidine + daily review of necessity.[2] }
C. difficile: from antibiotic disruption of gut flora. Send C. diff toxin for ANY new diarrhoea.[2] }
Antibiotic stewardship: minimise duration (5-7 days), de-escalate based on cultures, procalcitonin-guided. Each unnecessary antibiotic day increases resistance and C. diff risk.[1] }
VAP prevention bundle: head elevation 30-45° + daily SAT+SBT + oral chlorhexidine + subglottic suction + cuff pressure 20-30. Each measure independently reduces VAP.[2] }
Hand hygiene: WHO "5 Moments" — single most effective infection control measure.[2] }
Early mobilisation: reduces VAP, ICU-acquired weakness, delirium.[2] }
Resistant organisms: prolonged antibiotics select for MRSA, VRE, ESBL, CPE, C. difficile. Minimise exposure.[1] }
New fever in ICU CAP patient: differential = VAP, CRBSI, C. diff, UTI, drug fever, PE, non-infectious (inflammation).[1] }
Surveillance cultures: nasal swab (MRSA), rectal swab (VRE/ESBL/CPE) on admission + weekly. Guides empiric therapy if superinfection develops.[2] }
Selective digestive decontamination (SDD): controversial — reduces VAP but resistance concerns. Not standard in most ICUs.[2] }
Early extubation: shortest effective ventilation = lowest VAP risk. Daily SBT.[2] }
Stress ulcer prophylaxis: only for ventilation >48h or coagulopathy. Unnecessary PPI may increase C. diff risk.[2] }
Probiotics: may reduce C. diff risk in patients on broad-spectrum antibiotics (controversial).[2] }

Red flags

Nosocomial pneumonia: definitions

Pneumonia acquired in hospital is classified by where and how the patient acquired it. The terminology matters because the likely pathogens and empiric antibiotic choices differ from community-acquired pneumonia (CAP). The 2005 ATS/IDSA guidelines introduced the term HCAP (healthcare-associated pneumonia) for patients with recent hospitalisation, residence in a nursing home, home wound care, or recent IV antibiotics/chemotherapy — on the assumption that these patients harboured resistant organisms.[3]

HAP

Hospital-acquired pneumonia

New pneumonia >48 hours after hospital admission
NOT intubated at onset (distinguishes from VAP)
Incidence ~3-5 per 1,000 admissions, ~5-10 per 1,000 patient-days
Pathogens: enteric Gram-negatives (E. coli, Klebsiella, Enterobacter), S. aureus (incl. MRSA)
Mortality 15-25% (higher than CAP)
Empiric therapy guided by local antibiogram and MDR risk factors

VAP

Ventilator-associated pneumonia

New pneumonia >48 hours AFTER endotracheal intubation
The #1 nosocomial infection in the ICU
Incidence ~1-3 per 1,000 ventilator-days (was higher before prevention bundles)
Attributable mortality ~13%, attributable cost and length-of-stay substantial
Early-onset (<4 days): MSSA, pneumococcus, H. influenzae, antibiotic-sensitive GNs
Late-onset (≥4 days): MDR Pseudomonas, Acinetobacter, ESBL Klebsiella, MRSA

HCAP

Healthcare-associated — ABANDONED

Defined in 2005 ATS/IDSA guidelines — nursing-home residents, recent hospitalisation, home IV therapy/wound care, dialysis
Premised on assumption of high MDR risk → broad empiric antibiotics
REMOVED in 2016 IDSA/ATS guidelines — risk factors were poor predictors of MDR
Routine broad MDR coverage caused overtreatment and harm
Do NOT use the HCAP label — base empiric therapy on local antibiogram + patient risk factors instead

Why CAP patients are uniquely vulnerable

A patient admitted to the ICU for severe CAP is the prototype high-risk host for nosocomial superinfection because several risk factors converge simultaneously:[1]

Prolonged mechanical ventilation (the dominant risk — each extra ventilator day raises VAP risk ~1-3%)
Broad-spectrum antibiotics disrupt normal oropharyngeal and gut flora → colonisation with resistant organisms
Impaired consciousness / sedation → loss of the gag and cough reflexes → microaspiration
ETT cuff + supine position → pooled secretions bypass the cuff
Severity of illness and immune paralysis (critical-illness-associated immunosuppression)
Invasive devices: central lines (CRBSI), urinary catheters (CAUTI), NG tubes (sinusitis/aspiration)

Epidemiology and attributable burden

Nosocomial infection burden in ICU

1-3

VAP cases per 1,000

ventilator-days (post-bundle era)

~13%

Attributable VAP mortality

excess death attributable to VAP itself

+4-6 d

Extra ICU days

mean added length of stay per VAP

~$40k

Excess cost per VAP

USD attributable cost per episode

8.6/1000

CLABSI rate

central-line bloodstream infections per 1000 catheter-days

~3%

Risk per ventilator day

cumulative hazard rises with each day intubated

VAP develops in roughly 8-28% of mechanically ventilated patients depending on population and prevention-bundle adherence, with a median onset around day 5 of ventilation. The daily hazard is highest in the first week and accrues at roughly 1% per ventilator-day in the early period — the rationale that "the fastest way to prevent VAP is to extubate." Multiple observational studies estimate attributable mortality of ~13% (the excess death beyond the underlying critical illness), with markedly worse outcomes when the causative organism is MDR or when initial empiric therapy is inappropriate.[7][2]

Pathogenesis of VAP

VAP is fundamentally a disease of microaspiration of contaminated oropharyngeal secretions around the endotracheal tube (ETT) cuff. The ETT does not seal the airway — it is a foreign body that facilitates bacterial entry while paralysing the airway's mechanical defences.[2]

The four-step pathogenic cascade

How VAP develops — the pathogenic sequence

1. Colonisation of the oropharynx

Within hours of intubation, the oropharynx is colonised by enteric Gram-negatives and S. aureus. Broad-spectrum antibiotics and critical illness eradicate normal commensals (viridans streptococci), allowing pathogenic overgrowth. Gastric alkalinisation (PPIs, enteral feeds) allows gastric bacterial overgrowth that refluxes upward.

2. Formation of the ETT biofilm

Bacteria adhere to the polyvinyl-chloride ETT surface and secrete an exopolysaccharide matrix (biofilm) within 24h. Biofilm is resistant to both antibiotics and host immunity (bacteria 10-1000x more resistant inside). Fragments of biofilm embolise distally with each breath, inoculating the lower airway. Biofilm persists despite appropriate antibiotics.

3. Microaspiration around the cuff

The ETT cuff cannot form a perfect seal. Secretions pool in the subglottic space ("silent aspiration") and leak past folds in the cuff (longitudinal folds, or channels formed when cuff pressure fluctuates). Supine position, low cuff pressure, and patient transport increase leakage. Each intubated patient aspirates up to ~50% of pooled secretions.

4. Overwhelm host defences → pneumonia

Impaired mucociliary clearance (ETT bypasses, sedation suppresses cough), reduced neutrophil function (critical-illness immunoparalysis), and bacterial virulence overwhelm residual host defences. Inoculum reaches the alveoli → alveolar macrophage activation → neutrophil influx → consolidation = VAP. Each intubated day repeats the cycle; risk rises >1% per day.

[1]

Risk factors for VAP

Modifiable

Target the prevention bundle here

Supine positioning (Drakulovic: supine > doubles VAP risk)
Low cuff pressure (<20 cmH2O) → leakage around cuff
Prolonged ventilation (each day adds ~1-3% risk)
Over-sedation — abolishes cough and delays weaning
Re-intubation (disturbs cuff seal, aspirates gastric contents)
Enteral feeding via large-bore NG (reflux, gastric overdistension)
Inadequate hand hygiene by staff

Non-modifiable

Identify high-risk patients

Age >60, chronic lung disease, ARDS
Immunosuppression, burns, trauma (especially head injury)
Severity of illness (APACHE II), coma
Emergency intubation / intubation outside ICU
Pre-existing oropharyngeal/gastric colonisation with MDR organisms
Season (winter — more viral co-pathogens)

Microbiology: early vs late VAP

VAP prevention bundle components for severe CAP patients — FigureHead-up, oral care, sedation vacation, SBT readiness, circuit hygiene, and hand hygiene — the prevention bundle is the primary therapy.

The single most important microbiological principle: the likely pathogens depend on the time since intubation and on prior antibiotic exposure. Early VAP (within ~4 days) reflects aspiration of the patient's own community/commensal flora; late VAP reflects the MDR organisms that have colonised the ICU environment and the patient's airway under antibiotic pressure.[3]

Early-onset VAP

< 4 days of ventilation

Usually aspiration of endogenous community-acquired flora
Methicillin-sensitive S. aureus (MSSA)
Streptococcus pneumoniae
Haemophilus influenzae
Antibiotic-sensitive enteric Gram-negatives (E. coli, Klebsiella, Proteus)
Anaerobes (if frank aspiration)
Usually NOT MDR → narrower empiric therapy (e.g. ceftriaxone, ampicillin-sulbactam, or respiratory fluoroquinolone)
Better prognosis than late-onset VAP

Late-onset VAP

≥ 4 days of ventilation

Reflects ICU-acquired, antibiotic-selected MDR organisms
Pseudomonas aeruginosa (most common late pathogen)
Acinetobacter baumannii (highly MDR; carbapenem-resistant strains emerging)
Klebsiella / Enterobacter / Serratia (ESBL- and carbapenemase-producers)
MRSA (methicillin-resistant Staphylococcus aureus)
Stenotrophomonas maltophilia (often dually resistant)
Requires broad empiric MDR cover: anti-Pseudomonal beta-lactam + MRSA agent ± aminoglycoside/colistin; de-escalate on culture results
Higher mortality, longer ICU stay

The VAP prevention bundle

No single intervention eliminates VAP; the evidence base favours a multimodal "bundle" of cheap, low-risk measures applied together. The original Institute for Healthcare Improvement (IHI) VAP bundle and subsequent society guidelines converge on a core set of elements.[7][2]

The five core prevention elements

VAP prevention bundle — apply every element, every day

1. Semirecumbent position 30-45°

Elevate the head of the bed 30-45° unless contraindicated (spinal precautions, hypotension, prone ventilation). Drakulovic (Lancet 1999): supine vs semirecumbent — VAP 34% vs 8% (p=0.003). Supine position is an independent risk factor; the effect is largest during enteral feeding. Document HOB angle at every turn.

2. Daily sedation interruption (SAT) + spontaneous breathing trial (SBT)

Wake the patient daily (if safe) and assess readiness to wean. Coordinated SAT+SBT reduces duration of ventilation and VAP. The fastest way to prevent VAP is to extubate. Avoid over-sedation (abolishes cough, promotes pooling).

3. Oral care with chlorhexidine

0.12-2% chlorhexidine oral rinse/gel every 8-12h reduces oropharyngeal colonisation. Most benefit in cardiac surgery; benefit in general ICU is debated and recent meta-analyses question mortality signal, but it remains widely recommended. Mechanical tooth-brushing is an additive effect.

4. Subglottic secretion drainage (SSD) ETT

Use an ETT with a separate dorsal lumen above the cuff to continuously aspirate pooled subglottic secretions. Reduces early VAP (~50% RRR) especially in patients ventilated >48-72h. Cost-prevents at high VAP incidence. Not suitable for all patients ( cuff seal issues, suction trauma).

5. Maintain cuff pressure 20-30 cmH2O

Check cuff pressure at least every 8h. <20 → microaspiration; >30 → tracheal mucosal ischaemia and stenosis. Use a cuff-pressure manometer, not pilot-balloon palpation. Polyurethane/thin cuffs and cuff-shape (tapered) designs further reduce leakage.

6. Hand hygiene + gloves

WHO '5 Moments for Hand Hygiene'. The single most effective, lowest-cost infection-control measure. Staff hand contamination is the main route of cross-colonisation between patients. Monitor and feedback compliance.

7. DVT and stress ulcer prophylaxis

These are part of the original "ventilator bundle" not because they prevent VAP directly, but because the bundled approach reduces all-cause ICU morbidity. Stress ulcer prophylaxis: give only for proven indications (mechanical ventilation >48h OR coagulopathy) — unnecessary PPIs increase C. diff and may increase VAP.

8. Early mobilisation and minimising sedation

Mobilise as soon as haemodynamically stable. Reduces ICU-acquired weakness, delirium, duration of ventilation — and therefore VAP. Pair with SAT/SBT and a light sedation target (RASS 0 to -1).

Bundle element

Effect / evidence

Semirecumbent 30-45° — RCT-level, large effect (Drakulovic 1999)
Daily SAT + SBT — reduces ventilation duration (ABC, Awakening and Breathing Controlled trial)
Subglottic secretion drainage — ~50% RRR in early VAP, meta-analysis supported
Cuff pressure 20-30 cmH2O — mechanistic + observational
Oral chlorhexidine — reduces oropharyngeal colonisation; mortality signal debated
Hand hygiene (5 Moments) — reduces cross-transmission of MDR organisms

Adjunctive / controversial

Selective use

Selective digestive decontamination (SDD) / oropharyngeal decontamination (SOD) — reduces VAP and ICU mortality in some settings, but resistance-selection and C. diff concerns limit adoption outside low-resistance regions
Silver-coated ETT (North American Silver-Coated Endotracheal Tube trial) — delayed VAP onset but no mortality benefit, costly
Probiotics — reduce VAP in some meta-analyses; quality of evidence low
Routine stress ulcer prophylaxis — only for ventilation >48h or coagulopathy
Kinetic beds / continuous lateral rotation — modest VAP reduction, mainly neuro/trauma
Early tracheostomy — does NOT reduce VAP (TracMan, S&P trials)

Does NOT prevent VAP

Discard these

Routine sucralfate over PPI — no VAP advantage
Gastric overfeeding / large boluses — may increase reflux-aspiration
Scheduled ETT changes — biofilm reforms; changing tubes does not reduce VAP
Aerosolised antibiotics for prophylaxis — resistance, no routine role
Strict glucose control 81-108 (NICE-SUGAR) — hypoglycaemia harm, no VAP benefit

Diagnosis of VAP

VAP is a clinical diagnosis supported by microbiology — there is no single gold-standard test. The 2016 guideline does not mandate any one strategy; both invasive (bronchoscopic) and non-invasive (tracheal aspirate) sampling are acceptable, provided results are interpreted with the clinical picture and used to de-escalate antibiotics.[3]

Clinical criteria

The diagnosis requires a new or progressive infiltrate on imaging plus at least two of: fever >38°C, leucopenia (<4) or leucocytosis (>12), and purulent respiratory secretions. Sensitivity is high but specificity is modest — atelectasis, pulmonary oedema, PE, ARDS and drug reactions all mimic VAP. [1]

Clinical Pulmonary Infection Score (CPIS)

The CPIS (Pugin, 1991) combines six domains — fever, leucocyte count, secretions, oxygenation (PaO2/FiO2), radiography, and semi-quantitative tracheal-aspirate culture — into a score from 0 to 12.[6] A CPIS >6 supports VAP.

CPIS domain	0 points	1 point	2 points
Temperature (°C)	36.5-38.4	38.5-38.9	≤36 or ≥39
Leucocytes (x10&sup9;/L)	4-11	<4 or >11	<4 or >11 + bands ≥50%
Tracheal secretions	None	Non-purulent	Purulent
PaO2/FiO2 (mmHg)	>240 or ARDS	—	≤240 (no ARDS)
Chest radiograph	No infiltrate	Diffuse/patchy	Localised
Semi-quantitative culture	0 / pathogenic	1+ / pathogenic	2+ / pathogenic

Qualitative vs quantitative sampling

Non-invasive: endotracheal aspirate (qualitative/semi-quant)

Suction catheter through the ETT; sample sent for Gram stain + culture
Simple, cheap, no bronchoscopy, minimal risk
High sensitivity (~75-90%) — a NEGATIVE aspirate usefully EXCLUDES VAP
Low specificity (~70%) — oropharyngeal contamination overestimates pathogens
Best used as a "rule-out" and to guide de-escalation

Invasive: bronchoalveolar lavage (BAL) / protected specimen brush (PSB)

Bronchoscopically-directed or "blind" mini-BAL into the affected segment
Quantitative culture thresholds: BAL >10&sup4; CFU/mL (PSB >10³)
Higher specificity (~80-85%) — better discrimination of true pathogens
More expensive, needs expertise, transient hypoxaemia/bleeding risk
No consistent mortality benefit vs non-invasive strategy (meta-analyses)

Choosing a strategy

Either strategy is acceptable (2016 guideline); standardise within your unit
Obtain a lower-airway sample BEFORE starting or changing antibiotics
Use results to DE-ESCALATE therapy, not to decide whether to treat
Rapid molecular tests (e.g. BioFire, MRSA PCR) can guide early narrowing
Biomarkers (procalcitonin, CRP, sTREM-1) are adjuncts, not sole decision-makers

Antibiotic therapy and duration

VAP diagnosis and antibiotic stewardship pathway in the ICU — FigureSuspect VAP after 48 hours of ventilation; sample before antibiotics when safe; de-escalate with cultures and short courses.

Empiric therapy principles

Empiric therapy must cover the likely MDR pathogens based on time since intubation, prior antibiotics, local antibiogram, and unit resistance patterns.[3]

Early VAP (<4 days), no MDR risk factors: ceftriaxone, ampicillin-sulbactam, or a respiratory fluoroquinolone (cover MSSA, pneumococcus, sensitive enteric GNs).
Late VAP (≥4 days) or any MDR risk factor: two anti-Pseudomonal agents of different classes (e.g. piperacillin-tazobactam or cefepime or meropenem, PLUS an aminoglycoside or fluoroquinolone) PLUS MRSA cover (vancomycin or linezolid) if MRSA risk factors exist.
Carbapenem-resistant organisms: colistin or polymyxin B ± a second agent; consider high-dose meropenem extended-infusion if MIC allows.

De-escalate to the narrowest effective agent once culture and sensitivity results return (typically 48-72h). Inappropriate initial therapy (failure to cover the causative organism) doubles VAP mortality — the most important reason to err broad initially, then narrow.[3]

How long to treat: the PNEUMA trial

The PNEUMA trial (Chastre et al., JAMA 2003) is the landmark study establishing short-course therapy for VAP. It randomised 401 patients with microbiologically-confirmed VAP to 8 vs 15 days of appropriate antibiotics.[4]

PNEUMA trial — 8 vs 15 days of antibiotics for VAP

18.8%

28-day mortality (8d)

vs 17.6% (15d) — no difference

Similar

Recurrence rate

~25% both arms; higher with non-lactose-fermenters at 8d

Antibiotic-free days

13.1 vs 8.4 days favouring 8-day course

8 days

Recommended duration

2016 guideline default for uncomplicated VAP

Interpretation: Among patients with VAP caused by non-lactose-fermenting Gram-negatives (Pseudomonas, Acinetobacter, Stenotrophomonas), recurrence was higher with the 8-day course, prompting some experts to extend treatment to 10-14 days for these pathogens. Otherwise, an 8-day course is non-inferior to 15 days and reduces antibiotic exposure — the foundation of the 2016 guideline's recommendation for a 7-day course for both HAP and VAP (clinical response permitting).[3][4]

Beyond pneumonia: other ICU-acquired infections

VAP is the most visible nosocomial infection in a ventilated CAP patient, but the same risk factors — invasive devices, broad antibiotics, immunoparalysis — drive a cluster of related infections that must be screened for whenever a CAP patient develops new fever or inflammatory markers. [1]

Infection	Source	Key diagnostic step	Prevention bundle
CRBSI / CLABSI	Central venous catheter	Paired blood cultures (peripheral + from line); dwell time >5 d	Maximal barrier insertion, chlorhexidine prep, daily line necessity review, remove when not essential
Catheter-associated UTI (CAUTI)	Urinary catheter	Urine culture >10³ CFU/mL + symptoms; avoid treating asymptomatic bacteriuria	Avoid catheter; remove ASAP; closed drainage; sterile insertion
C. difficile infection	Antibiotic disruption of gut flora	Stool toxin EIA/NAAT (GDH + toxin); send for ANY new diarrhoea	Antimicrobial stewardship; avoid unnecessary PPIs; isolate promptly
Surgical site infection	Operative wound (if surgery)	Wound inspection, culture of discharge	Prophylactic antibiotic timing, normoglycaemia, normothermia
Sinusitis (nosocomial)	NG/ETT obstructing sinus drainage	CT sinuses + sinus aspiration cultures	Use orogastric over nasogastric tubes; semirecumbent position
Decubitus ulcer infection	Pressure injury	Wound swab/biopsy; deep tissue in sepsis	Regular turning, pressure-relieving mattress, skin care, nutrition

Management algorithm summary

Approach to suspected nosocomial infection in a ventilated CAP patient

1. Recognise the trigger

New fever >38°C, rising inflammatory markers (CRP/procalcitonin), purulent secretions, new/worsening oxygenation, new infiltrate on CXR, or haemodynamic instability. Do NOT assume it is infection — consider PE, drug fever, ARDS, atelectasis, pancreatitis.

2. Localise the source

Examine the patient: chest (auscultate, review CXR/CT), central line site and duration, urine output and catheter, abdomen (distension, diarrhoea → C. diff), wounds, sinuses. Send paired blood cultures (peripheral + each lumen of lines in situ >48h).

3. Sample before antibiotics

For suspected VAP: endotracheal aspirate or BAL for Gram stain and culture BEFORE starting/changing antibiotics. Send C. diff toxin for any new diarrhoea. Urine culture only if symptomatic. Consider rapid molecular panels.

4. Start empiric broad therapy

Cover likely MDR organisms based on time since intubation, prior antibiotics and local antibiogram. Two anti-Pseudomonals + MRSA cover if late VAP or MDR risk. Inappropriate initial therapy doubles mortality — go broad first.

5. Reassess at 48-72 hours

Review cultures, sensitivities and clinical course. De-escalate to the narrowest effective agent. Stop MRSA cover if no MRSA. If no infection confirmed and patient improving, consider stopping antibiotics entirely (antibiotic time-out).

6. Treat for the shortest effective duration

7-8 days for most VAP/HAP (PNEUMA trial). Extend to 10-14 days only for non-lactose-fermenting Gram-negatives, slow clinical response, undrained foci, or bacteraemia. Procalcitonin can support stopping decisions.

7. Reinforce the prevention bundle

Confirm head-of-bed 30-45°, daily SAT/SBT, oral care, cuff pressure 20-30, subglottic suction if available, line removal review, hand hygiene. Address modifiable risk factors to prevent recurrence and the next infection.

8. Source control and de-escalation

Remove infected lines (replace at new site if still needed), drain collections, relieve obstruction. Continue stewardship rounds to keep antibiotic pressure — and thus resistance and C. diff risk — as low as possible.

Prognosis

Outcomes after nosocomial infection in ICU

~13%

Attributable VAP mortality

excess death beyond underlying illness

Mortality with inappropriate initial Rx

emphasises empiric MDR cover then de-escalate

+4-6 d

Extra ICU stay per VAP

and additional mechanical-ventilation days

~40%

MDR late-VAP rate

SAQ — Ventilator-associated pneumonia in a CAP patient

10 minutes · 10 marks

A 68-year-old man is admitted to ICU with severe CAP (Streptococcus pneumoniae bacteraemia) requiring intubation. He is on day 6 of ventilation, having received ceftriaxone + azithromycin, then escalated to piperacillin-tazobactam on day 4 for ongoing sepsis. Today he spikes a fever of 38.9°C, has thick purulent secretions, and a new right lower lobe infiltrate on CXR. WBC 16.2, PaO2/FiO2 210 on FiO2 0.5/PEEP 8.

Clinical pearls — deep dive

High-yield nosocomial pneumonia and prevention pearls for the CICM/FFICM/EDIC exam

VAP = new pneumonia >48h after intubation. It is the #1 nosocomial infection in the ICU and the dominant superinfection in a ventilated CAP patient. Daily hazard accrues at ~1-3% per ventilator-day.[1]
HCAP is dead. The 2016 IDSA/ATS guidelines abandoned the HCAP category — its risk factors were poor predictors of MDR pathogens and routine broad coverage caused harm (nephrotoxicity, C. difficile). Base empiric therapy on the local antibiogram + patient-specific risk factors instead.[3]
Pathogenesis = microaspiration around the ETT cuff + biofilm. The ETT does not seal the airway; pooled subglottic secretions leak past folds in the cuff. Bacteria form a biofilm on the ETT within 24h that is 10-1000x more antibiotic-resistant and continuously embolises distally.[2]
Early vs late VAP decides empiric therapy. <4 days: MSSA, pneumococcus, sensitive GNs (narrower therapy, e.g. ceftriaxone). ≥4 days: Pseudomonas, Acinetobacter, ESBL Klebsiella, MRSA (broad MDR cover, then de-escalate).[3]
The VAP prevention bundle has 5 core elements: semirecumbent 30-45°, daily SAT + SBT, oral chlorhexidine, subglottic secretion drainage (when ventilated >48-72h), cuff pressure 20-30 cmH2O. Apply every element, every day.[7]
Semirecumbent position is the best-evidenced single measure. Drakulovic (Lancet 1999): VAP 8% semirecumbent vs 34% supine (p=0.003). Supine position is an independent, modifiable risk factor — especially during enteral feeding.[5]
The fastest way to prevent VAP is to extubate. Daily coordinated SAT + SBT reduces ventilation duration and VAP without increasing adverse events (ABC trial). Avoid over-sedation — it abolishes cough and delays weaning.[2]
CPIS >6 supports VAP (Pugin 1991) — combines fever, WCC, secretions, PaO2/FiO2, radiograph and semi-quantitative culture. High sensitivity, modest specificity. Do NOT use CPIS alone to start or stop antibiotics.[6][3]
Sample before you treat, then de-escalate. Obtain a lower-airway culture (tracheal aspirate or BAL) before changing antibiotics. Either qualitative or quantitative sampling is acceptable — results guide de-escalation, not the decision to treat.[3]
Inappropriate initial empiric therapy doubles VAP mortality. Err broad initially (two anti-Pseudomonals + MRSA cover if late/MDR risk), then narrow aggressively at 48-72h. This is the single most modifiable mortality risk.[3]
Treat for 7-8 days, not longer. PNEUMA trial (Chastre JAMA 2003): 8 vs 15 days — no difference in mortality or recurrence, more antibiotic-free days with 8 days. The 2016 guideline defaults to a 7-day course. Extend only for non-lactose-fermenters, slow response, undrained foci or bacteraemia.[4][3]
Non-lactose-fermenting Gram-negatives (Pseudomonas, Acinetobacter, Stenotrophomonas) need special attention — higher recurrence at 8 days, often MDR, may need 10-14 days and combination therapy (colistin/polymyxin for carbapenem-resistant strains).[4]
Cuff pressure 20-30 cmH2O — check every shift. <20 → microaspiration; >30 → tracheal ischaemia/stenosis. Use a manometer, not pilot-balloon palpation. Polyurethane and tapered cuffs further reduce leakage.[2]
Subglottic secretion drainage cuts early VAP ~50% — use an ETT with a dorsal suction port in patients expected to be ventilated >48-72h. Most cost-effective in high-VAP-incidence units.[7]
Hand hygiene (WHO 5 Moments) is the single most effective, lowest-cost infection-control measure. Staff hands are the main route of cross-colonisation with MDR organisms between patients. Monitor and feedback compliance.[2]
Stress ulcer prophylaxis only when indicated — mechanical ventilation >48h OR coagulopathy. Routine PPIs in low-risk patients increase C. difficile and may increase VAP; review daily and stop when indications lapse.[1]
Selective digestive decontamination (SDD/SOD) reduces VAP and may reduce ICU mortality, but concerns about resistance selection and C. diff limit use to low-resistance regions; not standard in most ANZ/UK/US units.[2]
Early tracheostomy does NOT reduce VAP (TracMan, S&P trials) — do not perform early tracheostomy for VAP prevention. Routine ETT changes and strict glucose control also do not help and may harm (NICE-SUGAR).[2]
New fever in a ventilated CAP patient — think broadly: VAP, CRBSI, C. difficile, CAUTI, sinusitis, drug fever, PE, ARDS, atelectasis. Examine, localise, and sample before empirically changing antibiotics.[1]
Surveillance cultures on admission + weekly (nasal MRSA, rectal VRE/ESBL/CPE) guide empiric therapy when superinfection develops and track unit resistance. Pair with an active antibiogram.[2]

Red flags — critical pitfalls

Critical pitfalls in nosocomial pneumonia

HCAP is abandoned (2016) — do NOT give broad MDR antibiotics purely on a nursing-home/recent-hospitalisation label. Use the local antibiogram + patient risk factors.[3]
Do NOT delay appropriate antibiotics in a sick patient to wait for bronchoscopy/BAL — inappropriate initial therapy doubles VAP mortality. Treat broad, sample, then de-escalate.[3]
CPIS or biomarkers (procalcitonin, CRP) must NOT be the sole basis to start or stop antibiotics in suspected VAP — the 2016 guideline explicitly advises against this.[3]
Do NOT prolong antibiotics beyond 7-8 days routinely — PNEUMA: no benefit over 8 days; longer courses drive resistance and C. difficile. Exception: non-lactose-fermenting GNs, slow response, undrained foci.[4]
Supine positioning is an independent VAP risk factor — keep head of bed 30-45° unless contraindicated. Drakulovic: VAP 34% supine vs 8% semirecumbent.[5]
Cuff pressure <20 cmH2O → microaspiration around the cuff — check every shift and keep 20-30 cmH2O.[2]
The ETT biofilm is a reservoir that antibiotics cannot eradicate — the only definitive prevention is early extubation; do not expect to "cure" VAP while a contaminated tube remains.[2]
Routine PPI stress-ulcer prophylaxis in low-risk patients increases C. difficile and may increase VAP — give only for ventilation >48h or coagulopathy, and review daily.[1]
Do NOT treat asymptomatic bacteriuria (catheterised patients) — it causes resistance without benefit. Treat CAUTI only with symptoms + culture.[2]
Non-compliance with hand hygiene is the #1 preventable cause of cross-colonisation with MDR organisms — never optional.[2]

References

[1]Martin-Loeches I, Torres A. Severe community-acquired pneumonia Eur Respir Rev, 2022.PMID 36517046
[2]Klompas M, et al. Notum palmitoleoyl-protein carboxylesterase regulates Fas cell surface death receptor-mediated apoptosis via the Wnt signaling pathway in colon adenocarcinoma Bioengineered, 2021.PMID 34402722
[3]Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society Clin Infect Dis, 2016.PMID 27418577
[4]Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial JAMA, 2003.PMID 14625336
[5]Drakulovic MB, Torres A, Bauer TT, et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial Lancet, 1999.PMID 10584721
[6]Pugin J, Auckenthaler R, Mili N, et al. [The diagnosis of pneumonia in the ventilated patient] Schweiz Med Wochenschr, 1990.PMID 2251483
[7]Muscedere J, Dodek P, Keenan S, et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention J Crit Care, 2008.PMID 18359430

[1] [1]

Clinical pearls

High-yight nosocomial complications points for the CICM/FFICM exam

VAP: #1 nosocomial infection in ventilated CAP patients. Different organisms from initial CAP (healthcare-associated).[1] }
CRBSI: from central venous catheter. Prevent with full barrier precautions + chlorhexidine + daily review of necessity.[2] }
C. difficile: from antibiotic disruption of gut flora. Send C. diff toxin for ANY new diarrhoea.[2] }
Antibiotic stewardship: minimise duration (5-7 days), de-escalate based on cultures, procalcitonin-guided. Each unnecessary antibiotic day increases resistance and C. diff risk.[1] }
VAP prevention bundle: head elevation 30-45° + daily SAT+SBT + oral chlorhexidine + subglottic suction + cuff pressure 20-30. Each measure independently reduces VAP.[2] }
Hand hygiene: WHO "5 Moments" — single most effective infection control measure.[2] }
Early mobilisation: reduces VAP, ICU-acquired weakness, delirium.[2] }
Resistant organisms: prolonged antibiotics select for MRSA, VRE, ESBL, CPE, C. difficile. Minimise exposure.[1] }
New fever in ICU CAP patient: differential = VAP, CRBSI, C. diff, UTI, drug fever, PE, non-infectious (inflammation).[1] }
Surveillance cultures: nasal swab (MRSA), rectal swab (VRE/ESBL/CPE) on admission + weekly. Guides empiric therapy if superinfection develops.[2] }
Selective digestive decontamination (SDD): controversial — reduces VAP but resistance concerns. Not standard in most ICUs.[2] }
Early extubation: shortest effective ventilation = lowest VAP risk. Daily SBT.[2] }
Stress ulcer prophylaxis: only for ventilation >48h or coagulopathy. Unnecessary PPI may increase C. diff risk.[2] }
Probiotics: may reduce C. diff risk in patients on broad-spectrum antibiotics (controversial).[2] }

Red flags

Nosocomial pneumonia: definitions

HAP

Hospital-acquired pneumonia

New pneumonia >48 hours after hospital admission
NOT intubated at onset (distinguishes from VAP)
Incidence ~3-5 per 1,000 admissions, ~5-10 per 1,000 patient-days
Pathogens: enteric Gram-negatives (E. coli, Klebsiella, Enterobacter), S. aureus (incl. MRSA)
Mortality 15-25% (higher than CAP)
Empiric therapy guided by local antibiogram and MDR risk factors

VAP

Ventilator-associated pneumonia

New pneumonia >48 hours AFTER endotracheal intubation
The #1 nosocomial infection in the ICU
Incidence ~1-3 per 1,000 ventilator-days (was higher before prevention bundles)
Attributable mortality ~13%, attributable cost and length-of-stay substantial
Early-onset (<4 days): MSSA, pneumococcus, H. influenzae, antibiotic-sensitive GNs
Late-onset (≥4 days): MDR Pseudomonas, Acinetobacter, ESBL Klebsiella, MRSA

HCAP

Healthcare-associated — ABANDONED

Defined in 2005 ATS/IDSA guidelines — nursing-home residents, recent hospitalisation, home IV therapy/wound care, dialysis
Premised on assumption of high MDR risk → broad empiric antibiotics
REMOVED in 2016 IDSA/ATS guidelines — risk factors were poor predictors of MDR
Routine broad MDR coverage caused overtreatment and harm
Do NOT use the HCAP label — base empiric therapy on local antibiogram + patient risk factors instead

Why CAP patients are uniquely vulnerable

A patient admitted to the ICU for severe CAP is the prototype high-risk host for nosocomial superinfection because several risk factors converge simultaneously:[1]

Prolonged mechanical ventilation (the dominant risk — each extra ventilator day raises VAP risk ~1-3%)
Broad-spectrum antibiotics disrupt normal oropharyngeal and gut flora → colonisation with resistant organisms
Impaired consciousness / sedation → loss of the gag and cough reflexes → microaspiration
ETT cuff + supine position → pooled secretions bypass the cuff
Severity of illness and immune paralysis (critical-illness-associated immunosuppression)
Invasive devices: central lines (CRBSI), urinary catheters (CAUTI), NG tubes (sinusitis/aspiration)

Epidemiology and attributable burden

Nosocomial infection burden in ICU

1-3

VAP cases per 1,000

ventilator-days (post-bundle era)

~13%

Attributable VAP mortality

excess death attributable to VAP itself

+4-6 d

Extra ICU days

mean added length of stay per VAP

~$40k

Excess cost per VAP

USD attributable cost per episode

8.6/1000

CLABSI rate

central-line bloodstream infections per 1000 catheter-days

~3%

Risk per ventilator day

cumulative hazard rises with each day intubated

Pathogenesis of VAP

The four-step pathogenic cascade

How VAP develops — the pathogenic sequence

1. Colonisation of the oropharynx

2. Formation of the ETT biofilm

3. Microaspiration around the cuff

4. Overwhelm host defences → pneumonia

[1]

Risk factors for VAP

Modifiable

Target the prevention bundle here

Supine positioning (Drakulovic: supine > doubles VAP risk)
Low cuff pressure (<20 cmH2O) → leakage around cuff
Prolonged ventilation (each day adds ~1-3% risk)
Over-sedation — abolishes cough and delays weaning
Re-intubation (disturbs cuff seal, aspirates gastric contents)
Enteral feeding via large-bore NG (reflux, gastric overdistension)
Inadequate hand hygiene by staff

Non-modifiable

Identify high-risk patients

Age >60, chronic lung disease, ARDS
Immunosuppression, burns, trauma (especially head injury)
Severity of illness (APACHE II), coma
Emergency intubation / intubation outside ICU
Pre-existing oropharyngeal/gastric colonisation with MDR organisms
Season (winter — more viral co-pathogens)

Microbiology: early vs late VAP

Early-onset VAP

< 4 days of ventilation

Usually aspiration of endogenous community-acquired flora
Methicillin-sensitive S. aureus (MSSA)
Streptococcus pneumoniae
Haemophilus influenzae
Antibiotic-sensitive enteric Gram-negatives (E. coli, Klebsiella, Proteus)
Anaerobes (if frank aspiration)
Usually NOT MDR → narrower empiric therapy (e.g. ceftriaxone, ampicillin-sulbactam, or respiratory fluoroquinolone)
Better prognosis than late-onset VAP

Late-onset VAP

≥ 4 days of ventilation

Reflects ICU-acquired, antibiotic-selected MDR organisms
Pseudomonas aeruginosa (most common late pathogen)
Acinetobacter baumannii (highly MDR; carbapenem-resistant strains emerging)
Klebsiella / Enterobacter / Serratia (ESBL- and carbapenemase-producers)
MRSA (methicillin-resistant Staphylococcus aureus)
Stenotrophomonas maltophilia (often dually resistant)
Requires broad empiric MDR cover: anti-Pseudomonal beta-lactam + MRSA agent ± aminoglycoside/colistin; de-escalate on culture results
Higher mortality, longer ICU stay

The VAP prevention bundle

The five core prevention elements

VAP prevention bundle — apply every element, every day

1. Semirecumbent position 30-45°

2. Daily sedation interruption (SAT) + spontaneous breathing trial (SBT)

3. Oral care with chlorhexidine

4. Subglottic secretion drainage (SSD) ETT

5. Maintain cuff pressure 20-30 cmH2O

6. Hand hygiene + gloves

7. DVT and stress ulcer prophylaxis

8. Early mobilisation and minimising sedation

Mobilise as soon as haemodynamically stable. Reduces ICU-acquired weakness, delirium, duration of ventilation — and therefore VAP. Pair with SAT/SBT and a light sedation target (RASS 0 to -1).

Bundle element

Effect / evidence

Semirecumbent 30-45° — RCT-level, large effect (Drakulovic 1999)
Daily SAT + SBT — reduces ventilation duration (ABC, Awakening and Breathing Controlled trial)
Subglottic secretion drainage — ~50% RRR in early VAP, meta-analysis supported
Cuff pressure 20-30 cmH2O — mechanistic + observational
Oral chlorhexidine — reduces oropharyngeal colonisation; mortality signal debated
Hand hygiene (5 Moments) — reduces cross-transmission of MDR organisms

Adjunctive / controversial

Selective use

Selective digestive decontamination (SDD) / oropharyngeal decontamination (SOD) — reduces VAP and ICU mortality in some settings, but resistance-selection and C. diff concerns limit adoption outside low-resistance regions
Silver-coated ETT (North American Silver-Coated Endotracheal Tube trial) — delayed VAP onset but no mortality benefit, costly
Probiotics — reduce VAP in some meta-analyses; quality of evidence low
Routine stress ulcer prophylaxis — only for ventilation >48h or coagulopathy
Kinetic beds / continuous lateral rotation — modest VAP reduction, mainly neuro/trauma
Early tracheostomy — does NOT reduce VAP (TracMan, S&P trials)

Does NOT prevent VAP

Discard these

Routine sucralfate over PPI — no VAP advantage
Gastric overfeeding / large boluses — may increase reflux-aspiration
Scheduled ETT changes — biofilm reforms; changing tubes does not reduce VAP
Aerosolised antibiotics for prophylaxis — resistance, no routine role
Strict glucose control 81-108 (NICE-SUGAR) — hypoglycaemia harm, no VAP benefit

Diagnosis of VAP

Clinical criteria

Clinical Pulmonary Infection Score (CPIS)

CPIS domain	0 points	1 point	2 points
Temperature (°C)	36.5-38.4	38.5-38.9	≤36 or ≥39
Leucocytes (x10&sup9;/L)	4-11	<4 or >11	<4 or >11 + bands ≥50%
Tracheal secretions	None	Non-purulent	Purulent
PaO2/FiO2 (mmHg)	>240 or ARDS	—	≤240 (no ARDS)
Chest radiograph	No infiltrate	Diffuse/patchy	Localised
Semi-quantitative culture	0 / pathogenic	1+ / pathogenic	2+ / pathogenic

Qualitative vs quantitative sampling

Non-invasive: endotracheal aspirate (qualitative/semi-quant)

Suction catheter through the ETT; sample sent for Gram stain + culture
Simple, cheap, no bronchoscopy, minimal risk
High sensitivity (~75-90%) — a NEGATIVE aspirate usefully EXCLUDES VAP
Low specificity (~70%) — oropharyngeal contamination overestimates pathogens
Best used as a "rule-out" and to guide de-escalation

Invasive: bronchoalveolar lavage (BAL) / protected specimen brush (PSB)

Bronchoscopically-directed or "blind" mini-BAL into the affected segment
Quantitative culture thresholds: BAL >10&sup4; CFU/mL (PSB >10³)
Higher specificity (~80-85%) — better discrimination of true pathogens
More expensive, needs expertise, transient hypoxaemia/bleeding risk
No consistent mortality benefit vs non-invasive strategy (meta-analyses)

Choosing a strategy

Either strategy is acceptable (2016 guideline); standardise within your unit
Obtain a lower-airway sample BEFORE starting or changing antibiotics
Use results to DE-ESCALATE therapy, not to decide whether to treat
Rapid molecular tests (e.g. BioFire, MRSA PCR) can guide early narrowing
Biomarkers (procalcitonin, CRP, sTREM-1) are adjuncts, not sole decision-makers

Antibiotic therapy and duration

Empiric therapy principles

Empiric therapy must cover the likely MDR pathogens based on time since intubation, prior antibiotics, local antibiogram, and unit resistance patterns.[3]

Early VAP (<4 days), no MDR risk factors: ceftriaxone, ampicillin-sulbactam, or a respiratory fluoroquinolone (cover MSSA, pneumococcus, sensitive enteric GNs).
Late VAP (≥4 days) or any MDR risk factor: two anti-Pseudomonal agents of different classes (e.g. piperacillin-tazobactam or cefepime or meropenem, PLUS an aminoglycoside or fluoroquinolone) PLUS MRSA cover (vancomycin or linezolid) if MRSA risk factors exist.
Carbapenem-resistant organisms: colistin or polymyxin B ± a second agent; consider high-dose meropenem extended-infusion if MIC allows.

How long to treat: the PNEUMA trial

PNEUMA trial — 8 vs 15 days of antibiotics for VAP

18.8%

28-day mortality (8d)

vs 17.6% (15d) — no difference

Similar

Recurrence rate

~25% both arms; higher with non-lactose-fermenters at 8d

Antibiotic-free days

13.1 vs 8.4 days favouring 8-day course

8 days

Recommended duration

2016 guideline default for uncomplicated VAP

Beyond pneumonia: other ICU-acquired infections

Infection	Source	Key diagnostic step	Prevention bundle
CRBSI / CLABSI	Central venous catheter	Paired blood cultures (peripheral + from line); dwell time >5 d	Maximal barrier insertion, chlorhexidine prep, daily line necessity review, remove when not essential
Catheter-associated UTI (CAUTI)	Urinary catheter	Urine culture >10³ CFU/mL + symptoms; avoid treating asymptomatic bacteriuria	Avoid catheter; remove ASAP; closed drainage; sterile insertion
C. difficile infection	Antibiotic disruption of gut flora	Stool toxin EIA/NAAT (GDH + toxin); send for ANY new diarrhoea	Antimicrobial stewardship; avoid unnecessary PPIs; isolate promptly
Surgical site infection	Operative wound (if surgery)	Wound inspection, culture of discharge	Prophylactic antibiotic timing, normoglycaemia, normothermia
Sinusitis (nosocomial)	NG/ETT obstructing sinus drainage	CT sinuses + sinus aspiration cultures	Use orogastric over nasogastric tubes; semirecumbent position
Decubitus ulcer infection	Pressure injury	Wound swab/biopsy; deep tissue in sepsis	Regular turning, pressure-relieving mattress, skin care, nutrition

Management algorithm summary

Approach to suspected nosocomial infection in a ventilated CAP patient

1. Recognise the trigger

2. Localise the source

3. Sample before antibiotics

4. Start empiric broad therapy

5. Reassess at 48-72 hours

6. Treat for the shortest effective duration

7. Reinforce the prevention bundle

8. Source control and de-escalation

Prognosis

Outcomes after nosocomial infection in ICU

~13%

Attributable VAP mortality

excess death beyond underlying illness

Mortality with inappropriate initial Rx

emphasises empiric MDR cover then de-escalate

+4-6 d

Extra ICU stay per VAP

and additional mechanical-ventilation days

~40%

SAQ — Ventilator-associated pneumonia in a CAP patient

10 minutes · 10 marks

Clinical pearls — deep dive

High-yield nosocomial pneumonia and prevention pearls for the CICM/FFICM/EDIC exam

VAP = new pneumonia >48h after intubation. It is the #1 nosocomial infection in the ICU and the dominant superinfection in a ventilated CAP patient. Daily hazard accrues at ~1-3% per ventilator-day.[1]
HCAP is dead. The 2016 IDSA/ATS guidelines abandoned the HCAP category — its risk factors were poor predictors of MDR pathogens and routine broad coverage caused harm (nephrotoxicity, C. difficile). Base empiric therapy on the local antibiogram + patient-specific risk factors instead.[3]
Pathogenesis = microaspiration around the ETT cuff + biofilm. The ETT does not seal the airway; pooled subglottic secretions leak past folds in the cuff. Bacteria form a biofilm on the ETT within 24h that is 10-1000x more antibiotic-resistant and continuously embolises distally.[2]
Early vs late VAP decides empiric therapy. <4 days: MSSA, pneumococcus, sensitive GNs (narrower therapy, e.g. ceftriaxone). ≥4 days: Pseudomonas, Acinetobacter, ESBL Klebsiella, MRSA (broad MDR cover, then de-escalate).[3]
The VAP prevention bundle has 5 core elements: semirecumbent 30-45°, daily SAT + SBT, oral chlorhexidine, subglottic secretion drainage (when ventilated >48-72h), cuff pressure 20-30 cmH2O. Apply every element, every day.[7]
Semirecumbent position is the best-evidenced single measure. Drakulovic (Lancet 1999): VAP 8% semirecumbent vs 34% supine (p=0.003). Supine position is an independent, modifiable risk factor — especially during enteral feeding.[5]
The fastest way to prevent VAP is to extubate. Daily coordinated SAT + SBT reduces ventilation duration and VAP without increasing adverse events (ABC trial). Avoid over-sedation — it abolishes cough and delays weaning.[2]
CPIS >6 supports VAP (Pugin 1991) — combines fever, WCC, secretions, PaO2/FiO2, radiograph and semi-quantitative culture. High sensitivity, modest specificity. Do NOT use CPIS alone to start or stop antibiotics.[6][3]
Sample before you treat, then de-escalate. Obtain a lower-airway culture (tracheal aspirate or BAL) before changing antibiotics. Either qualitative or quantitative sampling is acceptable — results guide de-escalation, not the decision to treat.[3]
Inappropriate initial empiric therapy doubles VAP mortality. Err broad initially (two anti-Pseudomonals + MRSA cover if late/MDR risk), then narrow aggressively at 48-72h. This is the single most modifiable mortality risk.[3]
Treat for 7-8 days, not longer. PNEUMA trial (Chastre JAMA 2003): 8 vs 15 days — no difference in mortality or recurrence, more antibiotic-free days with 8 days. The 2016 guideline defaults to a 7-day course. Extend only for non-lactose-fermenters, slow response, undrained foci or bacteraemia.[4][3]
Non-lactose-fermenting Gram-negatives (Pseudomonas, Acinetobacter, Stenotrophomonas) need special attention — higher recurrence at 8 days, often MDR, may need 10-14 days and combination therapy (colistin/polymyxin for carbapenem-resistant strains).[4]
Cuff pressure 20-30 cmH2O — check every shift. <20 → microaspiration; >30 → tracheal ischaemia/stenosis. Use a manometer, not pilot-balloon palpation. Polyurethane and tapered cuffs further reduce leakage.[2]
Subglottic secretion drainage cuts early VAP ~50% — use an ETT with a dorsal suction port in patients expected to be ventilated >48-72h. Most cost-effective in high-VAP-incidence units.[7]
Hand hygiene (WHO 5 Moments) is the single most effective, lowest-cost infection-control measure. Staff hands are the main route of cross-colonisation with MDR organisms between patients. Monitor and feedback compliance.[2]
Stress ulcer prophylaxis only when indicated — mechanical ventilation >48h OR coagulopathy. Routine PPIs in low-risk patients increase C. difficile and may increase VAP; review daily and stop when indications lapse.[1]
Selective digestive decontamination (SDD/SOD) reduces VAP and may reduce ICU mortality, but concerns about resistance selection and C. diff limit use to low-resistance regions; not standard in most ANZ/UK/US units.[2]
Early tracheostomy does NOT reduce VAP (TracMan, S&P trials) — do not perform early tracheostomy for VAP prevention. Routine ETT changes and strict glucose control also do not help and may harm (NICE-SUGAR).[2]
New fever in a ventilated CAP patient — think broadly: VAP, CRBSI, C. difficile, CAUTI, sinusitis, drug fever, PE, ARDS, atelectasis. Examine, localise, and sample before empirically changing antibiotics.[1]
Surveillance cultures on admission + weekly (nasal MRSA, rectal VRE/ESBL/CPE) guide empiric therapy when superinfection develops and track unit resistance. Pair with an active antibiogram.[2]

Red flags — critical pitfalls

Critical pitfalls in nosocomial pneumonia

HCAP is abandoned (2016) — do NOT give broad MDR antibiotics purely on a nursing-home/recent-hospitalisation label. Use the local antibiogram + patient risk factors.[3]
Do NOT delay appropriate antibiotics in a sick patient to wait for bronchoscopy/BAL — inappropriate initial therapy doubles VAP mortality. Treat broad, sample, then de-escalate.[3]
CPIS or biomarkers (procalcitonin, CRP) must NOT be the sole basis to start or stop antibiotics in suspected VAP — the 2016 guideline explicitly advises against this.[3]
Do NOT prolong antibiotics beyond 7-8 days routinely — PNEUMA: no benefit over 8 days; longer courses drive resistance and C. difficile. Exception: non-lactose-fermenting GNs, slow response, undrained foci.[4]
Supine positioning is an independent VAP risk factor — keep head of bed 30-45° unless contraindicated. Drakulovic: VAP 34% supine vs 8% semirecumbent.[5]
Cuff pressure <20 cmH2O → microaspiration around the cuff — check every shift and keep 20-30 cmH2O.[2]
The ETT biofilm is a reservoir that antibiotics cannot eradicate — the only definitive prevention is early extubation; do not expect to "cure" VAP while a contaminated tube remains.[2]
Routine PPI stress-ulcer prophylaxis in low-risk patients increases C. difficile and may increase VAP — give only for ventilation >48h or coagulopathy, and review daily.[1]
Do NOT treat asymptomatic bacteriuria (catheterised patients) — it causes resistance without benefit. Treat CAUTI only with symptoms + culture.[2]
Non-compliance with hand hygiene is the #1 preventable cause of cross-colonisation with MDR organisms — never optional.[2]

References

[1]Martin-Loeches I, Torres A. Severe community-acquired pneumonia Eur Respir Rev, 2022.PMID 36517046
[2]Klompas M, et al. Notum palmitoleoyl-protein carboxylesterase regulates Fas cell surface death receptor-mediated apoptosis via the Wnt signaling pathway in colon adenocarcinoma Bioengineered, 2021.PMID 34402722
[3]Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society Clin Infect Dis, 2016.PMID 27418577
[4]Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial JAMA, 2003.PMID 14625336
[5]Drakulovic MB, Torres A, Bauer TT, et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial Lancet, 1999.PMID 10584721
[6]Pugin J, Auckenthaler R, Mili N, et al. [The diagnosis of pneumonia in the ventilated patient] Schweiz Med Wochenschr, 1990.PMID 2251483
[7]Muscedere J, Dodek P, Keenan S, et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention J Crit Care, 2008.PMID 18359430